Townsquare Capital LLC Cuts Holdings in Gilead Sciences, Inc. $GILD

Townsquare Capital LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 41.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,151 shares of the biopharmaceutical company’s stock after selling 5,145 shares during the quarter. Townsquare Capital LLC’s holdings in Gilead Sciences were worth $794,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. GoalVest Advisory LLC increased its holdings in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth $26,000. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences during the 2nd quarter worth $27,000. Putney Financial Group LLC raised its holdings in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the period. Finally, Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at about $30,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Gilead Sciences Trading Up 1.7%

NASDAQ GILD opened at $141.95 on Friday. The firm’s fifty day moving average is $125.36 and its two-hundred day moving average is $119.59. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $142.20. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm has a market cap of $176.11 billion, a PE ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the company posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada increased their price target on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a report on Tuesday, January 20th. Rothschild & Co Redburn increased their target price on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. HSBC boosted their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. Truist Financial upped their price target on Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Wolfe Research raised their price target on Gilead Sciences from $150.00 to $155.00 and gave the stock an “outperform” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $136.36.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $139.89, for a total value of $1,398,900.00. Following the completion of the sale, the chief executive officer owned 556,698 shares in the company, valued at $77,876,483.22. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 257,397 shares of company stock worth $33,385,512 over the last ninety days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.